黄原胶寡糖是潜在的可商业化的功能性碳水化合物,其益生元功能具有一定的探究意义。该文通过对3个健康人粪便微生物的体外静态发酵和1个健康人粪便微生物的体外动态发酵的研究,探究黄原胶寡糖对粪便菌群结构及其代谢产物的影响。在体外静态粪便菌群发酵48 h时,通过薄层色谱法分析发现黄原胶寡糖基本被粪便菌群完全降解;与空白相比,黄原胶寡糖可显著增加发酵液中乙酸、丙酸和总短链脂肪酸的产量,浓度分别达到31.30、11.57和48.07 mmol/L;与果寡糖相比,黄原胶寡糖的丁酸产量(5.19 mmol/L)是果寡糖丁酸产量的2.66倍。在体外动态粪便菌群发酵中,黄原胶寡糖主要在24~48 h的发酵过程中被降解并显著增加乙酸、丙酸、丁酸、总短链脂肪酸的产量和NaOH的消耗量,乙酸、丙酸、丁酸和总短链脂肪酸的浓度分别达到49.44、28.64、1.65和79.72 mmol/L。在体外静态和动态粪便菌群发酵中,黄原胶寡糖可一致地降低Firmicutes/Bacteroidota的比例,增加毛螺菌科(Lachnospiraceae)和Parabacteroides属的相对丰度,进而改善肠道菌群结构。研究结果表明黄原胶寡糖具有潜在的益生活性。
Xanthan gum oligosaccharides (XGOS) is a potentially commercial functional carbohydrate. The effects of XGOS on gut microbiota was investigated. The results showed that in in vitro static batch fecal fermentation, XGOS was completely degraded after 48 h. The content of acetic acid, propionic acid and total short-chain fatty acids significantly increased which was 31.30, 11.57 and 48.07 mmol/L, respectively. The content of butyric acid was 5.19 mmol/L in XGOS fermentation, which was 2.66 times than that of FOS fermentation. In in vitro dynamic fecal fermentation, XGOS was degraded during 24-48 h fermentation. The consumption of acetic, propionic and butyric acid production and NaOH significantly was increased. The content of acetic, propionic, butyric acid and total short-chain fatty acids was 49.44, 28.64, 1.65 and 79.72 mmol/L, respectively, for 48 h. In in vitro static and dynamic fecal fermentation, XGOS could consistently decreased the ratio of Firmicutes/Bacteroidota and increased the abundance of Lachnospiraceae and Parabacteroides and improved the gut microbiota structure. The results indicate that XGOS has potential prebiotic properties.
[1] WANG B H,YAO M F,LV L,et al.The human microbiota in health and disease[J].Engineering,2017,3(1):71-82.
[2] MARCHESI J R,ADAMS D H,FAVA F,et al.The gut microbiota and host health:A new clinical frontier[J].Gut,2016,65(2):330-339.
[3] LEEMING E R,JOHNSON A J,SPECTOR T D,et al.Effect of diet on the gut microbiota:Rethinking intervention duration[J].Nutrients,2019,11(12):2862.
[4] GENTILE C L,WEIR T L.The gut microbiota at the intersection of diet and human health[J].Science,2018,362(6 416):776-780.
[5] HO A L,KOSIK O,LOVEGROVE A,et al.In vitro fermentability of xylo-oligosaccharide and xylo-polysaccharide fractions with different molecular weights by human faecal bacteria[J].Carbohydrate Polymers,2018,179:50-58.
[6] PERDIJK O,VAN BAARLEN P,FERNANDEZ-GUTIERREZ M M,et al.Sialyllactose and galactooligosaccharides promote epithelial barrier functioning and distinctly modulate microbiota composition and short chain fatty acid production in vitro[J].Frontiers in Immunology,2019,10:94.
[7] SALMINEN S,COLLADO M C,ENDO A,et al.The international scientific association of probiotics and prebiotics(ISAPP) consensus statement on the definition and scope of postbiotics[J].Nature Reviews Gastroenterology & Hepatology,2021,18(9):649-667.
[8] DE VADDER F,KOVATCHEVA-DATCHARY P,GONCALVES D,et al.Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits[J].Cell,2014,156(1-2):84-96.
[9] KELLY C J,ZHENG L,CAMPBELL E L,et al.Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function[J].Cell Host & Microbe,2015,17(5):662-671.
[10] FROST G,SLEETH M L,SAHURI-ARISOYLU M,et al.The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism[J].Nature Communications,2014,5:3611.
[11] XU J J,WANG R Y,ZHANG H T,et al.In vitro assessment of prebiotic properties of oligosaccharides derived from four microbial polysaccharides[J].LWT,2021,147:111544.
[12] XU J J,LIU W B,WU J R,et al.Metabolic profiles of oligosaccharides derived from four microbial polysaccharides by faecal inocula from type 2 diabetes patients[J].International Journal of Food Sciences and Nutrition,2021,72(8):1 083-1 094.
[13] 詹晓北,李志涛,张文龙,等.一种肠道体外可视化仿生反应器:CN108008088A[P].2018-05-08.
ZHAN X B,LI Z T,ZHANG W L,et al.A bionic reactor for intestinal visualization in vitro:CN108008088B[P].2019-08-20.
[14] LI Z T,HU G A,ZHU L,et al.In vitro digestion and fecal fermentation of highly resistant starch rice and its effect on the gut microbiota[J].Food Chemistry,2021,361:130095.
[15] MOON J S,SHIN S Y,CHOI H S,et al.In vitro digestion and fermentation properties of linear sugar-beet Arabinan and its oligosaccharides[J].Carbohydrate Polymers,2015,131:50-56.
[16] FU X D,LIU Z M,ZHU C L,et al.Nondigestible carbohydrates,butyrate,and butyrate-producing bacteria[J].Critical Reviews in Food Science and Nutrition,2019,59(sup1):S130-S152.
[17] VALDES A M,WALTER J,SEGAL E,et al.Role of the gut microbiota in nutrition and health[J].BMJ(Clinical Research Ed.),2018,361:k2179.
[18] HARRIS H C,EDWARDS C A,MORRISON D J.Impact of glycosidic bond configuration on short chain fatty acid production from model fermentable carbohydrates by the human gut microbiota[J].Nutrients,2017,9(1):E26.
[19] MANDALIYA D K,SESHADRI S.Short Chain Fatty Acids,pancreatic dysfunction and type 2 diabetes[J].Pancreatology,2019,19(4):617-622.
[20] HEIMANN E,NYMAN M,DEGERMAN E.Propionic acid and butyric acid inhibit lipolysis and de novo lipogenesis and increase insulin-stimulated glucose uptake in primary rat adipocytes[J].Adipocyte,2015,4(2):81-88.
[21] MAGNE F,GOTTELAND M,GAUTHIER L,et al.The firmicutes/bacteroidetes ratio:A relevant marker of gut dysbiosis in obese patients?[J].Nutrients,2020,12(5):1 474.
[22] WANG K,LIAO M F,ZHOU N,et al.Parabacteroides distasonis alleviates obesity and metabolic dysfunctions via production of succinate and secondary bile acids[J].Cell Reports,2019,26(1):222-235.e5.
[23] LOUIS P,YOUNG P,HOLTROP G,et al.Diversity of human colonic butyrate-producing bacteria revealed by analysis of the butyryl-CoA:Acetate CoA-transferase gene[J].Environmental Microbiology,2010,12(2):304-314.
